We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PDCO Stock Gains on the News of Acquisition Deal With Patient Square
Read MoreHide Full Article
Patterson Companies recently announced that it has entered into a definitive agreement to be acquired by Patient Square Capital (Patient Square), a dedicated healthcare investment firm.
Patterson’s shareholders will receive $31.35 in cash per share per the acquisition agreement with Patient Square, indicating a 49% premium over its 30-day volume-weighted average price as of Dec. 4, 2024. The total transaction is valued at approximately $4.1 billion, including the refinancing of Patterson’s receivables facilities.
Once the acquisition is completed, Patterson, which connects dental and animal health customers with a wide range of products and services, will become a privately held company. This transaction is expected to be closed in the fourth quarter of fiscal 2025, subject to the receipt of its shareholder approval, regulatory approvals and the satisfaction of other customary closing conditions.
Likely Trend of PDCO Stock Following the News
Following the announcement, shares of the company surged 34.5% and closed at $31.08 on Friday. In the year-to-date period, PDCO’s shares have gained 9.3% compared with the industry’s 2.5% growth. The S&P 500 increased 27.8% in the same time frame.
Meanwhile, PDCO currently has a market capitalization of $2.74 billion.
Image Source: Zacks Investment Research
More on PDCO’s Acquisition Deal With Patient Square
Patient Square is a dedicated healthcare investment firm with approximately $11 billion in assets under management as of Sept. 30, 2024. The firm aims to achieve strong investment returns by partnering with growth-oriented companies and top-tier management teams whose products, services and technologies improve health.
The merger agreement includes a 40-day “go-shop” period that permits the Patterson board and its advisors to actively solicit alternative acquisition proposals from third parties.
Recent Quarterly Performance of PDCO
Patterson Companies delivered an adjusted earnings per share of 47 cents in the second quarter of fiscal 2025, down 6% year over year. Its registered revenues improved 1.3% year over year to $1.67 billion.
In the last reported quarter, the Dental segment of PDCO reported revenues of $611.7 million, down 2.3% from the year-ago quarter. Revenues in the Animal Health segment totaled $1.05 billion, up 2.9% year over year on a reported basis.
PDCO’s Recent Developments
In November, Patterson Dental Supply, Inc., a subsidiary of PDCO, announced an agreement in principle between Patterson and PDS Health, a leading dental and medical support organization, to extend their strategic relationship through the end of 2027. This extension allows Patterson to continue as the premier distributor for all merchandise, services, technology and core equipment across PDS Health’s network of more than 1,000 supported practices nationwide.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PDCO Stock Gains on the News of Acquisition Deal With Patient Square
Patterson Companies recently announced that it has entered into a definitive agreement to be acquired by Patient Square Capital (Patient Square), a dedicated healthcare investment firm.
Patterson’s shareholders will receive $31.35 in cash per share per the acquisition agreement with Patient Square, indicating a 49% premium over its 30-day volume-weighted average price as of Dec. 4, 2024. The total transaction is valued at approximately $4.1 billion, including the refinancing of Patterson’s receivables facilities.
Once the acquisition is completed, Patterson, which connects dental and animal health customers with a wide range of products and services, will become a privately held company. This transaction is expected to be closed in the fourth quarter of fiscal 2025, subject to the receipt of its shareholder approval, regulatory approvals and the satisfaction of other customary closing conditions.
Likely Trend of PDCO Stock Following the News
Following the announcement, shares of the company surged 34.5% and closed at $31.08 on Friday. In the year-to-date period, PDCO’s shares have gained 9.3% compared with the industry’s 2.5% growth. The S&P 500 increased 27.8% in the same time frame.
Meanwhile, PDCO currently has a market capitalization of $2.74 billion.
Image Source: Zacks Investment Research
More on PDCO’s Acquisition Deal With Patient Square
Patient Square is a dedicated healthcare investment firm with approximately $11 billion in assets under management as of Sept. 30, 2024. The firm aims to achieve strong investment returns by partnering with growth-oriented companies and top-tier management teams whose products, services and technologies improve health.
The merger agreement includes a 40-day “go-shop” period that permits the Patterson board and its advisors to actively solicit alternative acquisition proposals from third parties.
Recent Quarterly Performance of PDCO
Patterson Companies delivered an adjusted earnings per share of 47 cents in the second quarter of fiscal 2025, down 6% year over year. Its registered revenues improved 1.3% year over year to $1.67 billion.
In the last reported quarter, the Dental segment of PDCO reported revenues of $611.7 million, down 2.3% from the year-ago quarter. Revenues in the Animal Health segment totaled $1.05 billion, up 2.9% year over year on a reported basis.
PDCO’s Recent Developments
In November, Patterson Dental Supply, Inc., a subsidiary of PDCO, announced an agreement in principle between Patterson and PDS Health, a leading dental and medical support organization, to extend their strategic relationship through the end of 2027. This extension allows Patterson to continue as the premier distributor for all merchandise, services, technology and core equipment across PDS Health’s network of more than 1,000 supported practices nationwide.
PDCO’s Zacks Rank & Stocks to Consider
PDCO carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks from the medical industry are Masimo (MASI - Free Report) , AngioDynamics (ANGO - Free Report) and Globus Medical (GMED - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 10.4% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.